

Proses korespondensi

Journal	Journal of Advanced Zoology
Volume	Vol. 44 No. 3 (2023)
e-ISSN	0253-7214
DOI	https://doi.org/10.17762/jaz.v44i3.1189
Authors	Septiana Indratmoko, Laela Hayu Nurani, Iis Wahyuningsih
Title	Enhancement of Icariin Aphrodisiac Effect by Solid-SNEDDS Method Using Shark Liver Oil Phase

Manuscript submission, bukti ojs:

Bukti ojs submission

The screenshot shows the author dashboard for the Journal of Advanced Zoology. The page title is "Bukti ojs submission". The browser address bar shows the URL: jazindia.com/index.php/jaz/authorDashboard/submission/336. The page header includes the journal name "Journal of Advanced Zoology" and a "Back to Submissions" link. The main content area displays the submission details for the article "Enhancement of Icariin Aphrodisiac Effect by Solid-SNEDDS Method Using Shark Liver Oil Phase" by Indratmoko et al. The submission is in the "Publication" stage, with sub-steps for "Submission", "Review", "Copyediting", and "Production". Under "Submission Files", there is one file: "1834 ENHANCEMENT OF ICARIIN APHRODISIAC EFFECT BY SOLID.docx", dated October 17, 2023, and identified as "Article Text". A "Download All Files" button is present. Below this, there is a "Pre-Review Discussions" section with an "Add discussion" button and a table with columns for Name, From, Last Reply, Replies, and Closed. The table currently shows "No Items".

Revisi_round 1 (masukan reviewer)

Bukti reviewer memberi masukan, screenshot email, jika pdf dari reviewer bisa berupa link:

The screenshot shows the author dashboard for the Journal of Advanced Zoology. The page title is "Journal of Advanced Zoology" and the URL is "jazindia.com/index.php/jaz/authorDashboard/submission/336". The dashboard displays the following sections:

- Round 1 Status:** Submission accepted.
- Reviewer's Attachments:** No Files.
- Revisions:** No Files.
- Review Discussions:** Add discussion.

The Review Discussions section contains one entry:

Name	From	Last Reply	Replies	Closed
Updates about your paper	admin_ojs3	-	0	<input type="checkbox"/>

The entry was sent on 2023-10-22 12:40 PM.

Line	Koreksi dari reviewer untuk diperbaiki
5	Another drug
14	How about bioavailability?
27	What is its chemical structure?
155	In english
204	In english
210	What is the importance of the dissolution test?

Bukti menyampaikan revisi

Bukti revisi, screenshot email, jika pdf hasil revisiannya bisa berupa link:


The screenshot shows the author dashboard for the Journal of Advanced Zoology. The page title is "Journal of Advanced Zoology" and the URL is "jazindia.com/index.php/jaz/authorDashboard/submission/336". The dashboard includes sections for "Round 1 Status" (Submission accepted), "Reviewer's Attachments" (No Files), "Revisions" (No Files), and "Review Discussions". A discussion entry is visible with the subject "Updates about your paper", from "admin_ojs3", dated "2023-10-22 12:40 PM", with 0 replies and a closed status.

Line	Koreksi dari reviewer untuk diperbaiki	Perbaikan:
5	Another drug	<i>..., such as sildenafil, tadalafil, vardenafil, and avanafil,</i>
14	How about bioavailability?	<i>Icariin exhibits poor solubility and low membrane permeability (water solubility of <math><100 \mu\text{g/mL}</math>, <math>\log (14).<="" <math>pk_a="7.07</math>)," a="" aglycon="" and="" as="" flavonoid="" i="" is="" it="" p="0.81</math>"></math>\log></i>
27	What is its chemical structure?	<i>Shark liver oil can dissolve icariin better than other oils because bottled fish oil contains squalene with a chemical structure of <math>\text{c}_{30}\text{h}_{50}< <math>\text{c}_{33}\text{h}_{40}\text{o}_{15}<="" almost="" i="" icariin="" is="" it="" level="" math>="" of="" polarity.<="" same="" similar="" so="" structure="" that="" the="" to="" which=""></math>\text{c}_{30}\text{h}_{50}<></i>

155	In english	<p><u>Table 4. Turbidity S-SNEDDS Icariin</u></p> <table border="1"> <thead> <tr> <th><i>Replication</i></th> <th><i>Transmittance (%)</i></th> </tr> </thead> <tbody> <tr> <td>1</td> <td>97,03</td> </tr> <tr> <td>2</td> <td>98,34</td> </tr> <tr> <td>3</td> <td>98,87</td> </tr> <tr> <td>Avarage ± SD</td> <td>98,08 ± 0,94</td> </tr> </tbody> </table>	<i>Replication</i>	<i>Transmittance (%)</i>	1	97,03	2	98,34	3	98,87	Avarage ± SD	98,08 ± 0,94
<i>Replication</i>	<i>Transmittance (%)</i>											
1	97,03											
2	98,34											
3	98,87											
Avarage ± SD	98,08 ± 0,94											
204	In english	<p><u>Table 7. Rest angle of S-SNEDDS Icariin</u></p> <table border="1"> <thead> <tr> <th><i>Repication</i></th> <th><i>Rest angle (°)</i></th> </tr> </thead> <tbody> <tr> <td>1</td> <td>33,663</td> </tr> <tr> <td>2</td> <td>34,837</td> </tr> <tr> <td>3</td> <td>36,979</td> </tr> <tr> <td><i>Avarage</i> ± SD</td> <td>35,159 ± 1,681</td> </tr> </tbody> </table>	<i>Repication</i>	<i>Rest angle (°)</i>	1	33,663	2	34,837	3	36,979	<i>Avarage</i> ± SD	35,159 ± 1,681
<i>Repication</i>	<i>Rest angle (°)</i>											
1	33,663											
2	34,837											
3	36,979											
<i>Avarage</i> ± SD	35,159 ± 1,681											
210	What is the importance of the dissolution test?	<p><i>The dissolution test describes the speed of release and dissolution of the active substance in the preparation. The importance of dissolution tests because a drug's availability depends on the substance's ability to dissolve into the solvent medium before being absorbed into the body.</i></p>										

Bukti accepted

Bukti accepted, screenshot email, jika pdf hasil yg akan terbit bisa berupa link, atau ss dari ojs published



ENHANCEMENT OF ICARIIN APHRODISIAC EFFECT BY SOLID-SNEDDS METHOD USING SHARK LIVER OIL PHASE

Septiana Indratmoko^{1*}, Laela H. Nurani², Iis Wahyuningsih²

¹ Department of Pharmacy, University of Al-Irsyad Cilacap, Cilacap 53225, Indonesia,

² Department of Pharmacy, University of Ahmad Dahlan, Yogyakarta 55185, Indonesia

*Corresponding author: indratmoko86@gmail.com

Abstract

The *Epimedium brevicornu Maxim* plant contains icariin, a flavonoid compound known for its aphrodisiac effects. However, icariin has low solubility and bioavailability. This study aims to find the best formula for S-SNEDDS icariin, its physical properties, characteristics, and aphrodisiac activity. Using the S-SNEDDS (Solid-Self Nanoemulsifying Drug Delivery System) method with shark liver oil phase is expected to increase the solubility and bioavailability of icariin. The optimum formula used is tween 80 (72.5%); PEG 400 (13.75%) and shark liver oil (13.75%). The optimal formula of S-SNEDDS icariin with the adsorption method to solid carriers requires aerosol 200 as much as 783 ± 28.86 mg per 1 mL. S-SNEDDS icariin has characteristics with an average emulsification time of 12.88 ± 0.26 seconds, transmittance value of $98.08 \pm 0.94\%$, droplet size 171.8 ± 8.9 nm, zeta potential -35.2 ± 1.1 mV, flow speed less than 10 seconds, resting angle 35.159° . The dissolution test of S-SNEDDS icariin is better than icariin instead of S-SNEDDS. S-SNEDDS icariin dose 50 mg/KgBW has a better aphrodisiac effect than pure icariin 100 mg/kgBW.

Keywords: aphrodisiac, icariin, shark liver oil, S-SNEDDS

1 I. Introduction

2 Sexual dysfunction disorders include reduced libido, abnormal ejaculation and erectile
3 dysfunction (1). Erectile dysfunction has a considerable impact on men's psychology and quality
4 of life, such as anxiety and depression (2,3). The use of drugs with the target of inhibiting
5 phosphodiesterase type 5, such as *sildenafil* is one of the main options for treating erectile
6 dysfunction (4). However, synthetic phosphodiesterase type 5 inhibitor compounds (PDE5) cause
7 some side effects such as headaches, priapism, redness and visual impairment (5).

8 Recently, compounds of plant origin are increasingly being studied for their safety in treating
9 sexual dysfunction (6). One of them is the epimedium plant. The main content in epimedium
10 plants is icariin (7). Icariin has various pharmacological effects such as anti-osteoporosis (8),
11 cardiovascular protection (9), anti-tumor (10), anti-inflammatory (11) and improvement of
12 sexual dysfunction (12). Based on research, icariin can fix erectile dysfunction problems by
13 inhibiting cGMP PDE5 (13).

14 The use of icariin for treatment is limited due to its low solubility in water, as it is a flavonoid
15 aglycon (14). In recent years, the method used to increase the solubility and reliability of active
16 substances is by making microemulsion formulas (15), nanoemulsions (16), mucoadhesive (17),
17 nanoparticles (18), liposome (19), transfersome (20), self-emulsifying (21), Self-Nanoemulsifying
18 (22), and solid-SNEDDS (23).

19 Solid-self nanoemulsifying drug delivery system (S-SNEDDS) is an isotropic mixture of oils,
20 surfactants, cosurfactants, drugs and carrier matrix that form nanoemulsions when meeting the
21 water phase (24). S-SNEDDS spread easily within the gastrointestinal tract, and the digestive
22 motility of the stomach and intestines provides the agitation necessary for emulsion systems (25).

Commented [MC1]: Another drug

Commented [MC2]: How about bioavailability?

23 In this study, the development of icariin nanoparticles made by the S-SNEDDS method was
24 carried out. Surfactants as emulsifiers of oil into water through the formation and stability guard
25 of the interface film layer, and co-surfactants help the task of surfactants as emulsifiers (26).
26 Shark liver oil can dissolve icariin better than other oils because bottled fish oil contains
27 squalene with a similiar chemical structure. The resulting icariin S-SNEDDS preparations were
28 subsequently carried out to characterize physical properties and test aphrodisiac activity in rat
29 test animals.

Commented [MC3]: what is its chemical structure?

30 31 **2. Material and Methods**

32 **Biomaterials and Chemicals**

33 Icariin (Lifmode, USA), standard icariin (Sigma-Aldrich 96%), aquades (Bratachem,
34 Indonesia), PEG 400 (Bratachem, Indonesia), Tween 80 (Bratachem, Indonesia), Shark liver oil
35 (Bumi Wijaya), aerosil 200 (Aloin Labora), sildenafil 50 mg (Novell Pharmaceutical
36 Laboratories).

37 **Experimental Animals**

38 Male and female white rats of the wistar strain (Lab. Pharmacology and Toxicology, Pharmacy
39 UMP). Ethical clearance for experimental animals has been registered with the ethics committee
40 of the Faculty of Medicine Jenderal Soedirman University with no. 024/KEPK/PE/V/2022. The
41 rats need to be acclimatized for at least 1 week before use and the weight was observed every
42 day to ensure the change in weight did not exceed 10%.

43 **Standard Curve of Icariin**

44 Standard curves are created using the maximum wavelength. The maximum wavelength is
45 obtained by scanning wavelengths from 200-400 nm. Accuracy was determined using a standard
46 solution of Icariin 1 mg in 10 mL of methanol. From the stock solution, concentrations of 6 ppm,
47 8 ppm, 10 ppm, 12 ppm, and 14 ppm, were made. Precision was determined by applying the
48 repetition method using a standard solution of Icariin with a concentration of 5 mg/mL.
49 Precision is performed by measuring absorbance using a 6-repeat UV-Vis spectrophotometer.

50 **S-SNEDDS Formula Optimization**

51 Making S-SNEDDS begins with the selection of the most optimal Liquid-SNEDDS formula. The
52 most optimal liquid-SNEDDS are then solidified into S-SNEDDS. Making solid SNEDSS based
53 on the publication of Buya et al (2020), using the adsorption onto solid carriers method using
54 aerosil 200. SNEDDS liquid icariin is inserted into a solid carrier namely aerosil 200 in a
55 mortar until a non-sticky powder is formed.

56 **Characterization of SNEDDS Icariin**

57 1. Emulsification Time Test

58 A total of 1 part of S-SNEDDS was dissolved in 500 mL aquadest using a magnetic
59 stirrer at a speed of 500 rpm at room temperature while calculating the time to achieve
60 emulsification using a stopwatch (27).

61 2. Turbidity Test

62 The determination of turbidity is carried out using the results of emulsification time. The
63 emulsion that has been obtained is measured absorption using a UV-VIS
64 spectrophotometer at a wavelength of 650 nm with an aquadest blank (28).

65 3. Particle size characteristics of S-SNEDDS icariin

66 *There are two parameters to determine the characterization of droplet size of icariin*
67 *nanoemulsions, namely droplet size and droplet size distribution with a Particle Size*
68 *Analyzer tool and zeta potential measurement. The test was carried out by taking a*
69 *preparation of S-SNEDDS icariin as much as 2 g dissolved in 100 mL water, the mixture*
70 *was homogenized using vortex. Then measured droplet size and droplet size distribution.*

71 4. Flow Speed Test

72 *A total of 100 g of icariin powder was flowed on the flowability tester test kit. It is noted*
73 *the time it takes for the powder to flow. The powder flow speed is said to be good when it*
74 *has a flow time of ≤ 10 seconds.*

75 5. Break Angle

76 *A total of 100 g of powder is input in the flowability tester test equipment, then cultured*
77 *for flow and recorded radius (r) and height (h). The angle of rest is calculated using the*
78 *formula:*

$$79 \quad \operatorname{tg} \alpha = \frac{h}{r} \quad (1)$$

80 *A stationary angle value of $< 40^\circ$ indicates that the granule flows easily (29).*

81 **Icariin Release Rate in S-SNEDDS System**

82 *Drug release or dissolution tests are carried out to determine the rate of release of the*
83 *active substance using a dissolution tester. One capsule is inserted into the dissolution tube, air*
84 *bubbles are removed from the surface of the tested preparation immediately the tool is executed*
85 *at a rate of 100 rotations per minute for 90 minutes.*

86 **Aphrodisiac Test S-SNEDDS Icariin**

87 *The S-SNEDDS icariin aphrodisiac test was performed using 25 male white rats and 25*
88 *female white rats. The rats were divided into five treatment groups, namely the negative control*
89 *group (aquadest), negative control (S-SNEDDS base), positive control (Sildenafil 50 mg), S-*
90 *SNEDDS icariin dose 50 mg / KgBW, pure icariin dose 100 mg / KgBW. Observation of sexual*
91 *activity was carried out using tools in the form of closed circuit television (CCTV) devices. The*
92 *observations made were coitus activities between male and female rats (30).*

93 **Data Analysis**

94 *Quantitative data on the activity of coitus obtained were analyzed using the oneway anova*
95 *method then continued with the LSD (Least Significant Different) test.*

96 3. Results and Discussion

98 **Standard curve, Accuracy, and Precision of Icariin**

99 *Based on the study, a standard curve was obtained with the equation $y = 0.0369x + 0.005$*
100 *with the value of the relation coefficient (r) = 0.9978. The value of the correlation coefficient*
101 *greater than 0.99 indicates that the analysis method used has good linearity and can provide a*
102 *response comparable to the concentration of analytes in the sample. Based on the value of %*
103 *recoveries obtained ranging from 98.13% to 103.00%, this is in line with the provisions of the*
104 *percentage of recovery analytes in the sample in the range of 95-105%. The RSD obtained in*
105 *precision measurement is equal to 1.84%. The value obtained is quite good because the RSD*
106 *value is less than 3.7%.*

107 **S-SNEDDS Formula Optimization**

108 *The optimum composition of the formula can be seen in Table 1 with a ratio of the composition*
 109 *of tween 80: PEG 400: Shark liver oil which is 72.5%: 13.75%: 13.75% which produces the*
 110 *highest percentage of Transmittance of 97.3±0.77%, the fast emulsification time is 12.48±0.82*
 111 *seconds and the smallest particle size is 17.82±0.62 nm.*

112 **Table 1. Material Composition, Transmittance Results and Emulsification Time Base L-SNEDDS**

Run	Comparison in %			Transmittance (%)	Emulsification time (second)	Particle Size (nm)
	Tween 80	PEG 400	Shark liver oil			
1	70	15	15	82.7±0.32	18.5±0.53	28.43±0.44
2	72.5	13.75	13.75	97.3±0.77	12.48±0.82	17.82±0.62
3	75	12.5	12.5	87.2±0.21	16.3±0.56	22.57±0.48

113
 114 *L-SNEDDS icariin is converted into S-SNEDDS icariin using the adsorption method to solid*
 115 *carriers by mixing aerosil 200 into SNEDDS icariin then stirring until homogeneous. This*
 116 *method is the simplest method also has advantages including better uniformity of granule size*
 117 *and the drug can be adsorbed up to 70% w/w with suitable carriers. The manufacture of S-*
 118 *SNEDDS icariin is carried out using adsorption techniques to solid carriers where aerosil 200*
 119 *used as an adsorbent has the property of being able to absorb L-SNEDDS formulations. The*
 120 *addition of aerosil is done little by little until the desired powder period is obtained. After the*
 121 *addition of aerosil 200 obtained a powder of pale yellow color. In 1 mL L-SNEDDS icariin*
 122 *requires 783.33 mg of aerosil 200 so that L-SNEDDS icariin can be adsorbed until a powder*
 123 *period is formed. Data on the results of the addition of aerosil 200 can be seen in Table 2.*

124 **Table 2. Addition of Aerosil 200 per 1 mL L-SNEDDS Icarin**

Adsorben	R1	R2	R3	Average ± SD
Aerosil (mg)	800	750	800	783.33± 28.86

125
 126 *The addition of aerosil 200 as an adsorbent can increase the ability to bind high moisture, the*
 127 *ability to overcome the stickiness of particles to each other so as to minimize friction that occurs*
 128 *between particles and maintain good flowability (31).*

129 **Characteristics of S-SNEDDS Icarin**

130 **1. Emulsification Time S-SNEDDS Icarin**

131 *Emulsification time is the time it takes for S-SNEDDS to form nanoemulsions starting when the*
 132 *initial 1 part of S-SNEDDS is dripped until the consistency of the nanoemulsion is formed when*
 133 *it encounters a liquid medium in the presence of mild agitation (32). An emulsification time test*
 134 *is performed to determine how fast the S-SNEDDS formula forms an emulsion. An S-SNEDDS*
 135 *formula is good when emulsification occurs rapidly in less than 1 minute with visually clear or*
 136 *transparent observations (33). Emulsification time testing performed 3 replications on the*
 137 *dissolution tester tool on aquadest media and artificial gastric fluid (AGF) media shown in*
 138 *Table 3.*

139

140

Table 3. Emulsification Time S-SNEDDS Icarin (15 mg)

Replication	Aquadest (second)	AGF (second)
1	13,05	17,53
2	12,57	18,12
3	13,01	18,87
Avarage ± SD	12,88 ± 0,26	18,17 ± 0,67

141

142

143

144

145

From the results of the emulsification time test, it was found that the emulsion formation time on aquadest media was $12.88 \pm 0,26$ seconds and on AGF media nanoemulsions were formed at $18.17 \pm 0,67$ seconds so that it can be said that S-SNEDDS icariin meets good criteria because the time needed is less than 1 minute (34).

146

2. Turbidity S-SNEDDS Icarin

147

148

149

150

151

152

153

154

The turbidity test aims to determine the level of clarity of the preparation, where a good transmittance value is close to 100%. The measurements were made using UV-Vis spectrophotometry at a wavelength of 650 nm. In testing, aquades are used as a blank solution or comparison because aquades are neutral and minimize interference with S-SNEDDS components when taking data.

The test was carried out using a solution that had passed the emulsification time test stage, taken 5 mL. Vortex 30 seconds and measured absorption at a wavelength of 650 nm with an aqueous blank to determine the level of clarity. Turbidity test results can be seen in Table 4.

155

Table 4. Turbidity S-SNEDDS Icarin

Replication	Transmittance (%)
1	97,03
2	98,34
3	98,87
Rata-rata ± SD	98,08 ± 0,94

Commented [MC4]: In english

156

157

158

159

From the data obtained, the transmittance value of S-SNEDDS icariin meets the requirements, which is close to 100%, with the average replication value obtained at $98.08 \pm 0,94$ %, which is the value of water transmittance.

160

3. Droplet Size and Zeta Potential of Icarin S-SNEDDS Nanoemulsion

161

162

163

164

165

166

167

168

169

170

171

In the particle size characteristics test, there are 2 parameters: droplet size measurement and zeta potential test. Droplet size or droplet size is important in making S-SNEDDS because it determines the size of droplets produced to determine the rate of drug release and absorption (35). Meanwhile, the Polydispersity Index (PI) value measures the molecular mass distribution in a particular sample, which is used as a parameter of uniformity and reliability of nanoemulsion manufacturing methods. There is also a zeta potential test to determine the characteristics of nanoemulsion preparations. The zeta potential value is a stability parameter of a system in which globules are dispersed through the presence of opposite forces between particles with the same charge when close together. Data on droplet size, PI, and zeta potential can be seen in Table 5.

172 **Table 5. Droplet Size, Polydispersity Index, and Zeta Potential of Icarin S-SNEDDS**
 173 **Nanoemulsion Zeta**

Replication	Droplet Size (nm)	Polydispersity Index (PI)	Zeta Potential (mV)
1	162,2	0,475	-34,7
2	173,6	0,491	-34,5
3	179,8	0,483	-36,5
Avarage ± SD	171,8±8,9	0,484±0,008	-35,2±1,1

174
 175 *The results of the droplet size test on S-SNEDDS icariin using the Particle Size Analyzer (PSA)*
 176 *tool obtained size of 171.8±8.9 nm, the value of the nanoparticle droplet size is in the range of*
 177 *20-200 nm so that the droplet size value of S-SNEDDS icariin is said to meet the range of*
 178 *requirements, where the smaller the droplet size, the faster the absorption, the solubility*
 179 *increases, and the pharmacological effect is faster. The Polydispersity Index (PI) value*
 180 *obtained an average value of 0.484±0.008 PI value below 1 or close to zero, which means that*
 181 *the distribution is good and said to be homogeneous.*
 182 *The zeta potential measurement of S-SNEDDS icariin is an average of -35.2±1.1 mV, and no*
 183 *flocculation occurs. Zeta potential values of more than ± 30 mV provide nanoemulsion droplet*
 184 *stability in the system so that flocculation does not occur. The negative charge from the droplet*
 185 *surface occurs due to free fatty acids derived from the S-SNEDDS component, namely*
 186 *surfactants, co-surfactants and shark liver oil containing fatty acids (36).*

187 **4. Icarin S-SNEDDS Flow Speed**

188 *The flow velocity test of S-SNEDDS icariin is performed to determine the characteristics of*
 189 *granules that are qualified to be produced to become oral solid preparations. Granules from S-*
 190 *SNEDDS icariin are expected to have a good flow speed so that the capsule preparation size*
 191 *can be uniform when filling into capsules. The granule is said to have a good flow speed. If the*
 192 *flow speed is not less than 10g/second or 100 g of granule the flow time is not more than 10*
 193 *seconds. The flow velocity test results can be seen in Table 6.*

194 **Table 6. Icarin S-SNEDDS Flow Speed**

Replication	Flow speed (seconds)
1	10
2	9,25
3	9,27
Avarage ± SD	9,50 ±0,42

195
 196 *A good flow speed is less than 10 seconds; the data obtained is the average flow speed carried*
 197 *out in 3 replications, which is 9.50±0.42 seconds.*
 198
 199

200 **5. S-SNEDDS Icarin Break Angle**

201 The rest angle test is a fixed angle between the cone-shaped particle pile and the horizontal
202 plane when the powder flows into the tool. The higher the granule cone, the higher the resting
203 angle. The values of the break angle can be seen in Table 7.

204

Tabel 7. Sudut Istirahat S-SNEDDS Icarin

Replikasi	Sudut Istirahat (°)
1	33,663
2	34,837
3	36,979
Rata-rata ± SD	35,159 ± 1,681

Commented [MC5]: In english


205

206 From the stationary angle test data in Table 7, it is known that the average test result is
207 $35.16^\circ \pm 1.681$, where this value meets the stationary angle requirement of $<40^\circ$, and it can be
208 said that the granule flows well (29).

209 Icarin Release Rate in S-SNEDDS base

210 Dissolution is releasing drug compounds from preparations and dissolving them in their solvent
211 media. The results of determining icarini levels based on the dissolution test of S-SNEDDS,
212 icarini in capsules and icarini without S-SNEDDS in capsules can be seen in Figure 1.

Commented [MC6]: What is the importance of the dissolution test?



213

214 **Figure 1. Dissolution of S-SNEDDS Icarin and Icarin in Aqueous and AGF Media**


215 From the dissolution test results for determining icarini levels in aqueous media, it can be seen
216 that icarini levels in S-SNEDDS preparations increase with increasing sampling time. Levels of
217 icarini not formulated in the form of S-SNEDDS have increased slowly. S-SNEDDS Icarin has a
218 better solution than Icarin without S-SNEDDS in Aqueous Media and AGF with a significant
219 differentiation ($p < 0.05$).

220

221 Aphrodisiac Test S-SNEDDS Icarin

222 S-SNEDDS icarini at a dose of 50 mg/KgBW provided an aphrodisiac effect in male white rats
223 for better intercourse (coitus) parameters when compared to pure icarini 100 mg/KgBW with a
224 significant differentiation ($p < 0.05$). S-SNEDDS formulations can increase the solubility of the

225 icariin compound and increase the aphrodisiac effectiveness of animal test rats. The results of
226 the aphrodisiac test between groups can be seen in Figure 2.



227

228

Figure 2. Coitus activity of test animals between treatment groups

229 *S-SNEDDS icariin at a dose of 50 mg/KgBW provided an aphrodisiac effect in male white rats*
230 *for better intercourse (coitus) parameters when compared to pure icariin 100 mg/KgBW with a*
231 *significant differentiation ($p < 0.05$). *S-SNEDDS formulations can increase the solubility of the*
232 *icariin compound and increase the aphrodisiac effectiveness of animal test rats. The results of*
233 *the aphrodisiac test between groups can be seen in Figure 2.**

234 *Icariin is a flavonoid group compound derived from the epimedium plant. This icariin has a role*
235 *in reducing the contraction of the smooth muscles of the corpus cavernous by increasing levels*
236 *of cyclic guanosine monophosphate (cGMP) to inhibit the formation of phosphodiesteration*
237 *enzyme type 5 (PDE5) (37). cGMP serves to increase blood flow to smooth muscles in the penis*
238 *area so that it can cause an increase in erection. In addition, flavonoids have a role in*
239 *increasing dihydro levels of epiandrosterone, which can increase testosterone levels and*
240 *encourage sexual activity (38).*

241 **4. Conclusion**

242 *The optimum formula used is tween 80 (72.5%): PEG 400 (13.75%) and shark liver oil (13.75%).*
243 *The optimal formula of S-SNEDDS icariin with the adsorption method to solid carriers requires*
244 *aerosol 200 as much as 783 ± 28.86 mg per 1 mL. S-SNEDDS icariin has characteristics with an*
245 *average emulsification time of 12.88 ± 0.26 seconds, transmittance value of $98.08 \pm 0.94\%$, droplet*
246 *size 171.8 ± 8.9 nm, zeta potential -35.2 ± 1.1 mV, flow speed less than 10 seconds, resting angle*
247 *35.159° . Dissolution of S-SNEDDS icariin is better than icariin without S-SNEDDS. S-SNEDDS*
248 *icariin has a higher effectiveness as an aphrodisiac compared to pure icariin.*

249 **Acknowledgments**

250 *We acknowledge the support grant and research funding received from The Ministry of*
251 *Education, Culture, Research and Technology in 2023.*


252 **References**

- 253 1. Kazemzadeh Atoofi M, Naziry G, Mohammadi M, Behzadipour S. Effect of Mindfulness
254 Based Sexual Relationship Therapy on Orgasm Quality and Sexual Function in Women
255 With Orgasmic Disorder: A Clinical Trial. *Iranian Journal of Psychiatry and Clinical*
256 *Psychology [Internet]. 2023 Jan 1;28(4):398–411. Available from:*

- 257 <https://ijpcp.iuims.ac.ir/article-1-3795-en.html>
- 258 2. Gong B, Ma M, Xie W, Yang X, Huang Y. Direct comparison of tadalafil with sildenafil
259 for the treatment of erectile dysfunction: a systematic review and meta - analysis.
260 *International Urology and Nephrology*. 2017;(0123456789).
- 261 3. Grice PT, Liu J, Gabrielson AT, Pearce I, Bivalacqua TJ, Modgil V. Drug delivery
262 options and therapeutic advances in the management of erectile dysfunction. *Expert*
263 *Opinion on Drug Delivery* [Internet]. 2020;17(9):1259–68. Available from:
264 <https://doi.org/10.1080/17425247.2020.1782383>
- 265 4. Abdelshakour MA, Abdel Salam RA, Hadad GM, Abo-ElMatty DM, Abdel Hameed EA.
266 HPLC-UV and UPLC-MS/MS methods for the simultaneous analysis of sildenafil,
267 vardenafil, and tadalafil and their counterfeits dapoxetine, paroxetine, citalopram,
268 tramadol, and yohimbine in aphrodisiac products. *RSC Advances*. 2021;11(14):8055–64.
- 269 5. Karakus S, Musicki B, Burnett AL. Mirabegron improves erectile function in men with
270 overactive bladder and erectile dysfunction: a 12-week pilot study. *International Journal*
271 *of Impotence Research* [Internet]. 2022 Sep 2;34(6):588–92. Available from:
272 <https://www.nature.com/articles/s41443-021-00455-2>
- 273 6. Turner D, Briken P, Grubbs J, Malandain L, Mestre-Bach G, Potenza MN, et al. The
274 World Federation of Societies of Biological Psychiatry guidelines on the assessment and
275 pharmacological treatment of compulsive sexual behaviour disorder. *Dialogues in clinical*
276 *neuroscience* [Internet]. 2022;24(1):10–69. Available from:
277 <https://doi.org/10.1080/19585969.2022.2134739>
- 278 7. Xie D, Xu Y, Cai W, Zhuo J, Zhu Z, Zhang H, et al. Icariin promotes osteogenic
279 differentiation by upregulating alpha-enolase expression. *Biochemistry and Biophysics*
280 *Reports* [Internet]. 2023 Jul;34:101471. Available from:
281 <https://linkinghub.elsevier.com/retrieve/pii/S2405580823000523>
- 282 8. Jiang J, He J, Xiao S, Shenyan J, Chen T, Pei D. Screening of superior anti-osteoporotic
283 flavonoids from *Epimedium Folium* with dual effects of reversing iron overload and
284 promoting osteogenesis. *Biomedical Chromatography* [Internet]. 2023 Sep 5;37(9).
285 Available from:
286 <https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bmc.5686>
- 287 9. Sai X, Li Z, Deng G, Wang L, Xiaowu W, Nasser MI, et al. Immunomodulatory effects of
288 icariin in a myocardial infarction mouse model. *Bioengineered* [Internet]. 2022 May
289 2;13(5):12504–15. Available from:
290 <https://www.tandfonline.com/doi/full/10.1080/21655979.2022.2076453>
- 291 10. Wang S, Gao J, Li Q, Ming W, Fu Y, Song L, et al. Study on the regulatory mechanism
292 and experimental verification of icariin for the treatment of ovarian cancer based on
293 network pharmacology. *Journal of Ethnopharmacology* [Internet]. 2020 Nov;262:113189.
294 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0378874120330713>
- 295 11. Jiang P, Zhou L, Du Z, Zhao L, Tang Y, Fei X, et al. Icariin alleviates autistic-like
296 behavior, hippocampal inflammation and vGlut1 expression in adult BTBR mice.
297 *Behavioural Brain Research* [Internet]. 2023 May;445:114384. Available from:
298 <https://linkinghub.elsevier.com/retrieve/pii/S016643282300102X>
- 299 12. Aboras SI, Korany MA, Abdine HH, Ragab MAA. HPLC/Fluorescence-Diode Array
300 Detection for Rapid and Reliable Determination of Illegal Synthetic Drugs in Male Sexual
301 Herbal and Honey Remedies: Comparative Study with UFLC–MS. *Journal of AOAC*
302 *INTERNATIONAL* [Internet]. 2022 Sep 6;105(5):1288–98. Available from:
303 <https://academic.oup.com/jaoac/article/105/5/1288/6550053>
- 304 13. Asfour HZ, Alhakamy NA, Fahmy UA, Ahmed OAA, Rizg WY, Felimban RI, et al. Zein-
305 Stabilized Nanospheres as Nanocarriers for Boosting the Aphrodisiac Activity of Icariin:
306 Response Surface Optimization and In Vivo Assessment. *Pharmaceutics* [Internet]. 2022
307 Jun 16;14(6):1279. Available from: <https://www.mdpi.com/1999-4923/14/6/1279>

- 308 14. Tang Cheng, Kun Meng 2, Xiaoming Chen 2, Hua Yao 2, Junqiong Kong 2, Fusu Li 2,
309 Haiyan Yin 2, Mingji Jin 2, Hao Liang 1 and QY 1. Preparation, Characterization, and In
310 Vivo Evaluation of Amorphous Icaritin Nanoparticles Prepared by a Reactive
311 Precipitation Technique. 2021;3:8–11.
- 312 15. Zheng Y, Zhao C, Chen B, Teng H, Ai C, Chen L. D- α -tocopherol polyethylene glycol
313 1000 succinate-based microemulsion delivery system: Stability enhancement of
314 physicochemical properties of luteolin. *Food Chemistry* [Internet]. 2023 Nov;426:136587.
315 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0308814623012050>
- 316 16. Das T, Chatterjee N, Chakraborty A, Banerjee A, Haiti SB, Datta S, et al. Fabrication of
317 rice bran oil nanoemulsion and conventional emulsion with Mustard Protein Isolate as a
318 novel excipient: Focus on shelf-life stability, lipid digestibility and cellular bioavailability.
319 *Food Hydrocolloids for Health* [Internet]. 2023 Dec;4:100143. Available from:
320 <https://linkinghub.elsevier.com/retrieve/pii/S2667025923000286>
- 321 17. Kumara BN, Shambhu R, Shim Y-B, Nirmal J, Prasad KS. Development of mucoadhesive
322 Timolol loaded chitosan-nanocomposite to treat glaucoma. *International Journal of*
323 *Biological Macromolecules* [Internet]. 2023 Dec;253:126917. Available from:
324 <https://linkinghub.elsevier.com/retrieve/pii/S014181302303814X>
- 325 18. Wang L, Mao J, Zhou Q, Deng Q, Zheng L, Shi J. A curcumin oral delivery system based
326 on sodium caseinate and carboxymethylpachymaran nanocomposites. *International*
327 *Journal of Biological Macromolecules* [Internet]. 2023 Dec;253:126698. Available from:
328 <https://linkinghub.elsevier.com/retrieve/pii/S014181302303595X>
- 329 19. ElNashar NT, Breitingner U, Breitingner H-G, Mansour S, Tammam SN. A liposomal
330 platform for the delivery of ion channel proteins for treatment of channelopathies —
331 Application in therapy of cystic fibrosis. *International Journal of Biological*
332 *Macromolecules* [Internet]. 2023 Dec;253:126652. Available from:
333 <https://linkinghub.elsevier.com/retrieve/pii/S0141813023035493>
- 334 20. Fitrya F, Fithri NA, Ahmadi A, Wijaya DP, Pitaloka AD. Formulation and
335 characterization of transfersome gel from *Parkia speciosa* extract using carbopol 940 and
336 polyvinyl alcohol. *Medicinal Plants - International Journal of Phytomedicines and*
337 *Related Industries* [Internet]. 2022;14(3):499–506. Available from:
338 [http://www.indianjournals.com/ijor.aspx?target=ijor:mpijpri&volume=14&issue=3&arti](http://www.indianjournals.com/ijor.aspx?target=ijor:mpijpri&volume=14&issue=3&article=016)
339 [cle=016](http://www.indianjournals.com/ijor.aspx?target=ijor:mpijpri&volume=14&issue=3&article=016)
- 340 21. Lin M, Wu L, Lu Y, Bao X, Zhong H, Dai Q, et al. Membrane fusion reverse micelle
341 platforms as potential oral nanocarriers for efficient internalization of free hydrophilic
342 peptides. *Nano Research* [Internet]. 2023 Jul 14;16(7):9768–80. Available from:
343 <https://link.springer.com/10.1007/s12274-023-5645-7>
- 344 22. El-Say KM, Alamri SH, Alsulimani HH, Alharbi WS, Omar AM, Safo MK, et al.
345 Incorporating valsartan in sesame oil enriched self-nanoemulsifying system-loaded
346 liquid tablets to improve its bioavailability. *International Journal of Pharmaceutics*
347 [Internet]. 2023 May;639:122966. Available from:
348 <https://linkinghub.elsevier.com/retrieve/pii/S0378517323003861>
- 349 23. Suhery WN, Mudhakar D, Sumirtapura YC, Pamudji JS. Comparative Bioavailability
350 Study of Solid Self-Nanoemulsifying Drug Delivery System of Fenofibric Acid in Healthy
351 Male Subjects. *Medical Principles and Practice* [Internet]. 2022;31(2):142–8. Available
352 from: <https://www.karger.com/Article/FullText/522380>
- 353 24. R. Gardouh A, M. Nasef A, Mostafa Y, Gad S. Impact on HDL and LDL of Hyperlipidemic
354 Rat Models: Designed Solid Self-Nanoemulsifying Drug Delivery Systems with
355 Atorvastatin and Ezetimibe combination. *Research Journal of Pharmacy and Technology*
356 [Internet]. 2022 Jun 28;24:2459–69. Available from:
357 <https://rjptonline.org/AbstractView.aspx?PID=2022-15-6-15>
- 358 25. Bravo-Alfaro DA, Ochoa-Rodríguez LR, Villaseñor-Ortega F, Luna-Barcenas G, García

- 359 HS. Self-nanoemulsifying drug delivery system (SNEDDS) improves the oral
360 bioavailability of betulinic acid. *Journal of Molecular Liquids* [Internet]. 2022
361 Oct;364:119946. Available from:
362 <https://linkinghub.elsevier.com/retrieve/pii/S016773222014842>
- 363 26. Abdullah M, Kanwal T, Shuja AA, Rao K, Rehman K, Kawish M, et al. Synthesis and
364 characterization of cinnamic acid based glyceride and its application for developing self-
365 nanoemulsifying drug delivery system for curcumin oral delivery. *Journal of Molecular*
366 *Structure* [Internet]. 2022 Sep;1263:133131. Available from:
367 <https://linkinghub.elsevier.com/retrieve/pii/S0022286022007918>
- 368 27. Chavda H, Patel J, Chavada G, Dave S, Patel A, Patel C. Self-Nanoemulsifying Powder of
369 Isotretinoin: Preparation and Characterization. *Journal of Powder Technology*.
370 2013;2013:1–9.
- 371 28. Jain S, Kumar N, Sharma R, Ghadi R, Date T, Bhargavi N, et al. Self-nanoemulsifying
372 formulation for oral delivery of sildenafil: effect on physicochemical attributes and in vivo
373 pharmacokinetics. *Drug Delivery and Translational Research* [Internet]. 2023 Mar
374 12;13(3):839–51. Available from: <https://link.springer.com/10.1007/s13346-022-01247-x>
- 375 29. Dewantara Putra Igna, Murwanti R, Rohman A, Sulaiman T. S. Optimizing Formulation
376 Of Mini Tablets Floating Ranitidine Hcl Using Fully Pregelatinized Starch (Manihot
377 Esculenta Crantz) With Simplex Lattice Design. *International Journal of Applied*
378 *Pharmaceutics* [Internet]. 2019 Apr 11;11(4):32–40. Available from:
379 <https://innovareacademics.in/journals/index.php/ijap/article/view/32657>
- 380 30. Nipanikar S, Nagore D, Chilange S. Evaluation of aphrodisiac activity of
381 AHPL/AYCAP/0114 capsule in sexually sluggish male rats. *Pharmacognosy Magazine*
382 [Internet]. 2018;14(55):264. Available from:
383 <https://phcog.com/article/view/2018/14/55s/s264-s267>
- 384 31. Sunkara D, Capece M. Influence of Material Properties on the Effectiveness of Glidants
385 Used to Improve the Flowability of Cohesive Pharmaceutical Powders. *AAPS*
386 *PharmSciTech* [Internet]. 2018 May 16;19(4):1920–30. Available from:
387 <http://link.springer.com/10.1208/s12249-018-1006-3>
- 388 32. Kuruba G, Narayana Reddy KA, Poli S, Ramnarayanan C. Quality by Design Based
389 Development of Self Nano Emulsifying Drug Delivery System of Ritonavir. *Journal of*
390 *Young Pharmacists*. 2020;12(3):215–20.
- 391 33. Bhagwat DA, Swami PA, Nadaf SJ, Choudhari PB, Kumbar VM, More HN, et al.
392 Capsaicin Loaded Solid SNEDDS for Enhanced Bioavailability and Anticancer Activity:
393 In-Vitro, In-Silico, and In-Vivo Characterization. *Journal of Pharmaceutical Sciences*
394 [Internet]. 2021 Jan;110(1):280–91. Available from:
395 <https://linkinghub.elsevier.com/retrieve/pii/S0022354920306122>
- 396 34. Navaneetha K, Rao VVB. Formulation and Evaluation of Solid-Supersaturable-SNEDDS
397 of Ibrutinib. *Indonesian Journal of Applied Pharmaceutics*. 2022;14(5).
- 398 35. Tashish AY, Shahba AAW, Alanazi FK, Kazi M. Adsorbent Precoating by Lyophilization:
399 A Novel Green Solvent Technique to Enhance Cinnarizine Release from Solid Self-
400 Nanoemulsifying Drug Delivery Systems (S-SNEDDS). *Pharmaceutics*. 2023;15(1).
- 401 36. Fisher KJ, Kinsey R, Mohamath R, Phan T, Liang H, Orr MT, et al. Semi-synthetic
402 terpenoids with differential adjuvant properties as sustainable replacements for shark
403 squalene in vaccine emulsions. *npj Vaccines*. 2023;8(1):1–19.
- 404 37. Ozturk M, Hakeem KR. *Plant and Human Health, Volume 1 Ethnobotany and Physiology*.
405 Switzerland: Speinger International Publishing AG; 2019.
- 406 38. Sun X-G, Pang X, Liang H-Z, Zhang J, Wang B, Li Q, et al. New prenylated flavonoid
407 glycosides derived from *Epimedium wushanense* by β -glucosidase hydrolysis and their
408 testosterone production-promoting effects. *Chinese Journal of Natural Medicines*
409 [Internet]. 2022 Sep;20(9):712–20. Available from:



ENHANCEMENT OF ICARIIN APHRODISIAC EFFECT BY SOLID-SNEDDS METHOD USING SHARK LIVER OIL PHASE

Septiana Indratmoko^{1*}, Laela H. Nurani², Iis Wahyuningsih²

¹ Department of Pharmacy, University of Al-Irsyad Cilacap, Cilacap 53225, Indonesia,

² Department of Pharmacy, University of Ahmad Dahlan, Yogyakarta 55185, Indonesia

*Corresponding author: indratmoko86@gmail.com

Abstract

The *Epimedium brevicornu Maxim* plant contains icariin, a flavonoid compound known for its aphrodisiac effects. However, icariin has low solubility and bioavailability. This study aims to find the best formula for S-SNEDDS icariin, its physical properties, characteristics, and aphrodisiac activity. Using the S-SNEDDS (Solid-Self Nanoemulsifying Drug Delivery System) method with shark liver oil phase is expected to increase the solubility and bioavailability of icariin. The optimum formula used is tween 80 (72.5%): PEG 400 (13.75%) and shark liver oil (13.75%). The optimal formula of S-SNEDDS icariin with the adsorption method to solid carriers requires aerosol 200 as much as 783 ± 28.86 mg per 1 mL. S-SNEDDS icariin has characteristics with an average emulsification time of 12.88 ± 0.26 seconds, transmittance value of $98.08 \pm 0.94\%$, droplet size 171.8 ± 8.9 nm, zeta potential -35.2 ± 1.1 mV, flow speed less than 10 seconds, resting angle 35.159° . The dissolution test of S-SNEDDS icariin is better than icariin instead of S-SNEDDS. S-SNEDDS icariin dose 50 mg/KgBW has a better aphrodisiac effect than pure icariin 100 mg/kgBW.

Keywords: aphrodisiac, icariin, shark liver oil, S-SNEDDS

1. Introduction

Sexual dysfunction disorders include reduced libido, abnormal ejaculation and erectile dysfunction (1). Erectile dysfunction has a considerable impact on men's psychology and quality of life, such as anxiety and depression (2,3). The use of drugs with the target of inhibiting phosphodiesterase type 5, such as sildenafil, tadalafil, vardenafil, and avanafil, is one of the main options for treating erectile dysfunction (4). However, synthetic phosphodiesterase type 5 inhibitor compounds (PDE5) cause some side effects such as headaches, priapism, redness and visual impairment (5).

Recently, compounds of plant origin are increasingly being studied for their safety in treating sexual dysfunction (6). One of them is the epimedium plant. The main content in epimedium plants is icariin (7). Icariin has various pharmacological effects such as anti-osteoporosis (8), cardiovascular protection (9), anti-tumor (10), anti-inflammatory (11) and improvement of sexual dysfunction (12). Based on research, icariin can fix erectile dysfunction problems by inhibiting cGMP PDE5 (13).

The use of icariin for treatment is limited due to its low solubility in water, and results in minimal bioavailability. Icariin exhibits poor solubility and low membrane permeability (water solubility of <100 $\mu\text{g/mL}$, $\log P = 0.81$ and $pK_a = 7.07$), as it is a flavonoid aglycon (14). In recent years, the method used to increase the solubility and reliability of active substances is by making microemulsion formulas (15), nanoemulsions (16), mucoadhesive (17), nanoparticles (18), liposome (19), transfersome (20), self-emulsifying (21), Self-Nanoemulsifying (22), and solid-SNEDDS (23).

Solid-self nanoemulsifying drug delivery system (S-SNEDDS) is an isotropic mixture of oils, surfactants, cosurfactants, drugs and carrier matrix that form nanoemulsions when meeting the

water phase (24). S-SNEDDS spread easily within the gastrointestinal tract, and the digestive motility of the stomach and intestines provides the agitation necessary for emulsion systems (25).

In this study, the development of icariin nanoparticles made by the S-SNEDDS method was carried out. Surfactants as emulsifiers of oil into water through the formation and stability guard of the interface film layer, and co-surfactants help the task of surfactants as emulsifiers (26). Shark liver oil can dissolve icariin better than other oils because bottled fish oil contains squalene with a chemical structure of $C_{30}H_{50}$ which is similar to the structure of icariin $C_{33}H_{40}O_{15}$ so that it is almost the same level of polarity. The resulting icariin S-SNEDDS preparations were subsequently carried out to characterize physical properties and test aphrodisiac activity in rat test animals.

2. Material and Methods

Biomaterials and Chemicals

Icariin (Lifmode, USA), standard icariin (Sigma-Aldrich 96%), aquades (Bratachem, Indonesia), PEG 400 (Bratachem, Indonesia), Tween 80 (Bratachem, Indonesia), Shark liver oil (Bumi Wijaya), aerosil 200 (Aloin Labora), sildenafil 50 mg (Novell Pharmaceutical Laboratories).

Experimental Animals

Male and female white rats of the wistar strain (Lab. Pharmacology and Toxicology, Pharmacy UMP). Ethical clearance for experimental animals has been registered with the ethics committee of the Faculty of Medicine Jenderal Soedirman University with no. 024/KEPK/PE/V/2022. The rats need to be acclimatized for at least 1 week before use and the weight was observed every day to ensure the change in weight did not exceed 10%.

Standard Curve of Icariin

Standard curves are created using the maximum wavelength. The maximum wavelength is obtained by scanning wavelengths from 200-400 nm. Accuracy was determined using a standard solution of Icariin 1 mg in 10 mL of methanol. From the stock solution, concentrations of 6 ppm, 8 ppm, 10 ppm, 12 ppm, and 14 ppm, were made. Precision was determined by applying the repetition method using a standard solution of Icariin with a concentration of 5 mg/mL. Precision is performed by measuring absorbance using a 6-repeat UV-Vis spectrophotometer.

S-SNEDDS Formula Optimization

Making S-SNEDDS begins with the selection of the most optimal Liquid-SNEDDS formula. The most optimal liquid-SNEDDS are then solidified into S-SNEDDS. Making solid SNEDSS based on the publication of Buya et al (2020), using the adsorption onto solid carriers method using aerosil 200. SNEDDS liquid icariin is inserted into a solid carrier namely aerosil 200 in a mortar until a non-sticky powder is formed.

Characterization of SNEDDS Icariin

1. Emulsification Time Test

A total of 1 part of S-SNEDDS was dissolved in 500 mL aquadest using a magnetic stirrer at a speed of 500 rpm at room temperature while calculating the time to achieve emulsification using a stopwatch (27).

2. Turbidity Test

The determination of turbidity is carried out using the results of emulsification time. The emulsion that has been obtained is measured absorption using a UV-VIS spectrophotometer at a wavelength of 650 nm with an aquadest blank (28).

3. *Particle size characteristics of S-SNEDDS icariin*

There are two parameters to determine the characterization of droplet size of icariin nanoemulsions, namely droplet size and droplet size distribution with a Particle Size Analyzer tool and zeta potential measurement. The test was carried out by taking a preparation of S-SNEDDS icariin as much as 2 g dissolved in 100 mL water, the mixture was homogenized using vortex. Then measured droplet size and droplet size distribution.

4. *Flow Speed Test*

A total of 100 g of icariin powder was flowed on the flowability tester test kit. It is noted the time it takes for the powder to flow. The powder flow speed is said to be good when it has a flow time of ≤ 10 seconds.

5. *Break Angle*

A total of 100 g of powder is input in the flowability tester test equipment, then cultured for flow and recorded radius (r) and height (h). The angle of rest is calculated using the formula:

$$\operatorname{tg}\alpha = \frac{h}{r} \quad (1)$$

A stationary angle value of $<40^\circ$ indicates that the granule flows easily (29).

Icariin Release Rate in S-SNEDDS System

Drug release or dissolution tests are carried out to determine the rate of release of the active substance using a dissolution tester. One capsule is inserted into the dissolution tube, air bubbles are removed from the surface of the tested preparation immediately the tool is executed at a rate of 100 rotations per minute for 90 minutes.

Aphrodisiac Test S-SNEDDS Icariin

The S-SNEDDS icariin aphrodisiac test was performed using 25 male white rats and 25 female white rats. The rats were divided into five treatment groups, namely the negative control group (aquadest), negative control (S-SNEDDS base), positive control (Sildenafil 50 mg), S-SNEDDS icariin dose 50 mg / KgBW, pure icariin dose 100 mg / KgBW. Observation of sexual activity was carried out using tools in the form of closed circuit television (CCTV) devices. The observations made were coitus activities between male and female rats (30).

Data Analysis

Quantitative data on the activity of coitus obtained were analyzed using the oneway anova method then continued with the LSD (Least Significant Different) test.

3. Results and Discussion

Standard curve, Accuracy, and Precision of Icariin

Based on the study, a standard curve was obtained with the equation $y = 0.0369x + 0.005$ with the value of the relation coefficient (r) = 0.9978. The value of the correlation coefficient greater than 0.99 indicates that the analysis method used has good linearity and can provide a response comparable to the concentration of analytes in the sample. Based on the value of %

recoveries obtained ranging from 98.13% to 103.00%, this is in line with the provisions of the percentage of recovery analytes in the sample in the range of 95-105%. The RSD obtained in precision measurement is equal to 1.84%. The value obtained is quite good because the RSD value is less than 3.7%.

S-SNEDDS Formula Optimization

The optimum composition of the formula can be seen in Table 1 with a ratio of the composition of tween 80: PEG 400: Shark liver oil which is 72.5%: 13.75%: 13.75% which produces the highest percentage of Transmittance of $97.3 \pm 0.77\%$, the fast emulsification time is 12.48 ± 0.82 seconds and the smallest particle size is 17.82 ± 0.62 nm.

Table 1. Material Composition, Transmittance Results and Emulsification Time Base L-SNEDDS

Run	Comparison in %			Transmittance (%)	Emulsification time (second)	Particle Size (nm)
	Tween 80	PEG 400	Shark liver oil			
1	70	15	15	82.7 ± 0.32	18.5 ± 0.53	28.43 ± 0.44
2	72.5	13.75	13.75	97.3 ± 0.77	12.48 ± 0.82	17.82 ± 0.62
3	75	12.5	12.5	87.2 ± 0.21	16.3 ± 0.56	22.57 ± 0.48

L-SNEDDS icariin is converted into S-SNEDDS icariin using the adsorption method to solid carriers by mixing aerosil 200 into SNEDDS icariin then stirring until homogeneous. This method is the simplest method also has advantages including better uniformity of granule size and the drug can be adsorbed up to 70% w/w with suitable carriers. The manufacture of S-SNEDDS icariin is carried out using adsorption techniques to solid carriers where aerosil 200 used as an absorbent has the property of being able to absorb L-SNEDDS formulations. The addition of aerosil is done little by little until the desired powder period is obtained. After the addition of aerosil 200 obtained a powder of pale yellow color. In 1 mL L-SNEDDS icariin requires 783.33 mg of aerosil 200 so that L-SNEDDS icariin can be absorbed until a powder period is formed. Data on the results of the addition of aerosil 200 can be seen in Table 2.

Table 2. Addition of Aerosil 200 per 1 mL L-SNEDDS Icariin

Adsorben	R1	R2	R3	Average \pm SD
Aerosil (mg)	800	750	800	783.33 ± 28.86

The addition of aerosil 200 as an adsorbent can increase the ability to bind high moisture, the ability to overcome the stickiness of particles to each other so as to minimize friction that occurs between particles and maintain good flowability (31).

Characteristics of S-SNEDDS Icariin

1. Emulsification Time S-SNEDDS Icariin

Emulsification time is the time it takes for S-SNEDDS to form nanoemulsions starting when the initial 1 part of S-SNEDDS is dripped until the consistency of the nanoemulsion is formed when it encounters a liquid medium in the presence of mild agitation (32). An emulsification time test is performed to determine how fast the S-SNEDDS formula forms an emulsion. An S-SNEDDS formula is good when emulsification occurs rapidly in less than 1 minute with visually clear or

transparent observations (33). Emulsification time testing performed 3 replications on the dissolution tester tool on aquadest media and artificial gastric fluid (AGF) media shown in Table 3.

Table 3. Emulsification Time S-SNEDDS Icariin (15 mg)

Replication	Aquadest (second)	AGF (second)
1	13,05	17,53
2	12,57	18,12
3	13,01	18,87
Avarage ± SD	12,88 ± 0,26	18,17 ± 0,67

From the results of the emulsification time test, it was found that the emulsion formation time on aquadest media was $12.88 \pm 0,26$ seconds and on AGF media nanoemulsions were formed at $18.17 \pm 0,67$ seconds so that it can be said that S-SNEDDS icariin meets good criteria because the time needed is less than 1 minute (34).

2. Turbidity S-SNEDDS Icariin

The turbidity test aims to determine the level of clarity of the preparation, where a good transmittance value is close to 100%. The measurements were made using UV-Vis spectrophotometry at a wavelength of 650 nm. In testing, aquades are used as a blank solution or comparison because aquades are neutral and minimize interference with S-SNEDDS components when taking data.

The test was carried out using a solution that had passed the emulsification time test stage, taken 5 mL. Vortex 30 seconds and measured absorption at a wavelength of 650 nm with an aqueous blank to determine the level of clarity. Turbidity test results can be seen in Table 4.

Table 4. Turbidity S-SNEDDS Icariin

Replication	Transmittance (%)
1	97,03
2	98,34
3	98,87
Avarage ± SD	98,08 ± 0,94

From the data obtained, the transmittance value of S-SNEDDS icariin meets the requirements, which is close to 100%, with the average replication value obtained at $98.08 \pm 0,94$ %, which is the value of water transmittance.

3. Droplet Size and Zeta Potential of Icariin S-SNEDDS Nanoemulsion

In the particle size characteristics test, there are 2 parameters: droplet size measurement and zeta potential test. Droplet size or droplet size is important in making S-SNEDDS because it determines the size of droplets produced to determine the rate of drug release and absorption (35). Meanwhile, the Polydispersity Index (PI) value measures the molecular mass distribution in a particular sample, which is used as a parameter of uniformity and reliability of nanoemulsion manufacturing methods. There is also a zeta potential test to determine the characteristics of nanoemulsion preparations. The zeta potential value is a stability parameter of a system in which globules are dispersed through the presence of opposite forces between

particles with the same charge when close together. Data on droplet size, PI, and zeta potential can be seen in Table 5.

Table 5. Droplet Size, Polydispersity Index, and Zeta Potential of Icariin S-SNEDDS Nanoemulsion Zeta

Replication	Droplet Size (nm)	Polydispersity Index (PI)	Zeta Potential (mV)
1	162,2	0,475	-34,7
2	173,6	0,491	-34,5
3	179,8	0,483	-36,5
<i>Avarage ± SD</i>	<i>171,8±8,9</i>	<i>0,484±0,008</i>	<i>-35,2±1,1</i>

The results of the droplet size test on S-SNEDDS icariin using the Particle Size Analyzer (PSA) tool obtained size of 171.8 ± 8.9 nm, the value of the nanoparticle droplet size is in the range of 20-200 nm so that the droplet size value of S-SNEDDS icariin is said to meet the range of requirements, where the smaller the droplet size, the faster the absorption, the solubility increases, and the pharmacological effect is faster. The Polydispersity Index (PI) value obtained an average value of 0.484 ± 0.008 PI value below 1 or close to zero, which means that the distribution is good and said to be homogeneous.

The zeta potential measurement of S-SNEDDS icariin is an average of -35.2 ± 1.1 mV, and no flocculation occurs. Zeta potential values of more than ± 30 mV provide nanoemulsion droplet stability in the system so that flocculation does not occur. The negative charge from the droplet surface occurs due to free fatty acids derived from the S-SNEDDS component, namely surfactants, co-surfactants and shark liver oil containing fatty acids (36).

4. Icariin S-SNEDDS Flow Speed

The flow velocity test of S-SNEDDS icariin is performed to determine the characteristics of granules that are qualified to be produced to become oral solid preparations. Granules from S-SNEDDS icariin are expected to have a good flow speed so that the capsule preparation size can be uniform when filling into capsules. The granule is said to have a good flow speed. If the flow speed is not less than 10g/second or 100 g of granule the flow time is not more than 10 seconds. The flow velocity test results can be seen in Table 6.

Table 6. Icariin S-SNEDDS Flow Speed

Replication	Flow speed (seconds)
1	10
2	9,25
3	9,27
<i>Avarage ± SD</i>	<i>9,50 ±0,42</i>

A good flow speed is less than 10 seconds; the data obtained is the average flow speed carried out in 3 replications, which is 9.50 ± 0.42 seconds.

5. S-SNEDDS Icariin Break Angle

The rest angle test is a fixed angle between the cone-shaped particle pile and the horizontal plane when the powder flows into the tool. The higher the granule cone, the higher the resting angle. The values of the break angle can be seen in Table 7.

Table 7. Rest angle of S-SNEDDS Icariin

Repication	Rest angle (°)
1	33,663
2	34,837
3	36,979
Avarage ± SD	35,159 ± 1,681

From the stationary angle test data in Table 7, it is known that the average test result is $35.16^\circ \pm 1.681$, where this value meets the stationary angle requirement of $<40^\circ$, and it can be said that the granule flows well (29).

Icariin Release Rate in S-SNEDDS base

Dissolution is releasing drug compounds from preparations and dissolving them in their solvent media. The dissolution test describes the speed of release and dissolution of the active substance in the preparation. The importance of dissolution tests because a drug's availability depends on the substance's ability to dissolve into the solvent medium before being absorbed into the body.

The results of determining icariin levels based on the dissolution test of S-SNEDDS, icariin in capsules and icariin without S-SNEDDS in capsules can be seen in Figure 1.




Figure 1. Dissolution of S-SNEDDS Icariin and Icariin in Aqueous and AGF Media

From the dissolution test results for determining icariin levels in aqueous media, it can be seen that icariin levels in S-SNEDDS preparations increase with increasing sampling time. Levels of icariin not formulated in the form of S-SNEDDS have increased slowly. S-SNEDDS Icariin has a better solution than Icariin without S-SNEDDS in Aqueous Media and AGF with a significant differentiation ($p < 0.05$).

Aphrodisiac Test S-SNEDDS Icariin

S-SNEDDS icariin at a dose of 50 mg/KgBW provided an aphrodisiac effect in male white rats for better intercourse (coitus) parameters when compared to pure icariin 100 mg/KgBW with a significant differentiation ($p < 0.05$). S-SNEDDS formulations can increase the solubility of the icariin compound and increase the aphrodisiac effectiveness of animal test rats. The results of the aphrodisiac test between groups can be seen in Figure 2.




Figure 2. *Coitus activity of test animals between treatment groups*

S-SNEDDS icariin at a dose of 50 mg/KgBW provided an aphrodisiac effect in male white rats for better intercourse (coitus) parameters when compared to pure icariin 100 mg/KgBW with a significant differentiation ($p < 0.05$). S-SNEDDS formulations can increase the solubility of the icariin compound and increase the aphrodisiac effectiveness of animal test rats. The results of the aphrodisiac test between groups can be seen in Figure 2.

Icariin is a flavonoid group compound derived from the epimedium plant. This icariin has a role in reducing the contraction of the smooth muscles of the corpus cavernous by increasing levels of cyclic guanosine monophosphate (cGMP) to inhibit the formation of phosphodiesterase enzyme type 5 (PDE5) (37). cGMP serves to increase blood flow to smooth muscles in the penis area so that it can cause an increase in erection. In addition, flavonoids have a role in increasing dihydro levels of epiandrosterone, which can increase testosterone levels and encourage sexual activity (38).

4. Conclusion

The optimum formula used is tween 80 (72.5%): PEG 400 (13.75%) and shark liver oil (13.75%). The optimal formula of S-SNEDDS icariin with the adsorption method to solid carriers requires aerosol 200 as much as 783 ± 28.86 mg per 1 mL. S-SNEDDS icariin has characteristics with an average emulsification time of 12.88 ± 0.26 seconds, transmittance value of $98.08 \pm 0.94\%$, droplet size 171.8 ± 8.9 nm, zeta potential -35.2 ± 1.1 mV, flow speed less than 10 seconds, resting angle 35.159° . Dissolution of S-SNEDDS icariin is better than icariin without S-SNEDDS. S-SNEDDS icariin has a higher effectiveness as an aphrodisiac compared to pure icariin.

Acknowledgments

We acknowledge the support grant and research funding received from The Ministry of Education, Culture, Research and Technology in 2023.

References

1. Kazemzadeh Atoofi M, Naziry G, Mohammadi M, Behzadipour S. Effect of Mindfulness Based Sexual Relationship Therapy on Orgasm Quality and Sexual Function in Women With Orgasmic Disorder: A Clinical Trial. *Iranian Journal of Psychiatry and Clinical Psychology* [Internet]. 2023 Jan 1;28(4):398–411. Available from: <https://ijpcp.iuims.ac.ir/article-1-3795-en.html>
2. Gong B, Ma M, Xie W, Yang X, Huang Y. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. *International Urology and Nephrology*. 2017;(0123456789).
3. Grice PT, Liu J, Gabrielson AT, Pearce I, Bivalacqua TJ, Modgil V. Drug delivery options and therapeutic advances in the management of erectile dysfunction. *Expert Opinion on Drug Delivery* [Internet]. 2020;17(9):1259–68. Available from: <https://doi.org/10.1080/17425247.2020.1782383>
4. Abdelshakour MA, Abdel Salam RA, Hadad GM, Abo-ElMatty DM, Abdel Hameed EA. HPLC-UV and UPLC-MS/MS methods for the simultaneous analysis of sildenafil, vardenafil, and tadalafil and their counterfeits dapoxetine, paroxetine, citalopram, tramadol, and yohimbine in aphrodisiac products. *RSC Advances*. 2021;11(14):8055–64.
5. Karakus S, Musicki B, Burnett AL. Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study. *International Journal of Impotence Research* [Internet]. 2022 Sep 2;34(6):588–92. Available from: <https://www.nature.com/articles/s41443-021-00455-2>
6. Turner D, Briken P, Grubbs J, Malandain L, Mestre-Bach G, Potenza MN, et al. The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder. *Dialogues in clinical neuroscience* [Internet]. 2022;24(1):10–69. Available from: <https://doi.org/10.1080/19585969.2022.2134739>
7. Xie D, Xu Y, Cai W, Zhuo J, Zhu Z, Zhang H, et al. Icariin promotes osteogenic differentiation by upregulating alpha-enolase expression. *Biochemistry and Biophysics Reports* [Internet]. 2023 Jul;34:101471. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2405580823000523>
8. Jiang J, He J, Xiao S, Shenyuan J, Chen T, Pei D. Screening of superior anti-osteoporotic flavonoids from *Epimedium Folium* with dual effects of reversing iron overload and promoting osteogenesis. *Biomedical Chromatography* [Internet]. 2023 Sep 5;37(9). Available from: <https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bmc.5686>
9. Sai X, Li Z, Deng G, Wang L, Xiaowu W, Nasser MI, et al. Immunomodulatory effects of icariin in a myocardial infarction mouse model. *Bioengineered* [Internet]. 2022 May 2;13(5):12504–15. Available from: <https://www.tandfonline.com/doi/full/10.1080/21655979.2022.2076453>
10. Wang S, Gao J, Li Q, Ming W, Fu Y, Song L, et al. Study on the regulatory mechanism and experimental verification of icariin for the treatment of ovarian cancer based on network pharmacology. *Journal of Ethnopharmacology* [Internet]. 2020 Nov;262:113189. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0378874120330713>
11. Jiang P, Zhou L, Du Z, Zhao L, Tang Y, Fei X, et al. Icariin alleviates autistic-like behavior, hippocampal inflammation and vGlut1 expression in adult BTBR mice. *Behavioural Brain Research* [Internet]. 2023 May;445:114384. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S016643282300102X>
12. Aboras SI, Korany MA, Abdine HH, Ragab MAA. HPLC/Fluorescence-Diode Array Detection for Rapid and Reliable Determination of Illegal Synthetic Drugs in Male Sexual Herbal and Honey Remedies: Comparative Study with UFLC–MS. *Journal of AOAC INTERNATIONAL* [Internet]. 2022 Sep 6;105(5):1288–98. Available from:

- <https://academic.oup.com/jaoac/article/105/5/1288/6550053>
13. Asfour HZ, Alhakamy NA, Fahmy UA, Ahmed OAA, Rizg WY, Felimban RI, et al. Zein-Stabilized Nanospheres as Nanocarriers for Boosting the Aphrodisiac Activity of Icariin: Response Surface Optimization and In Vivo Assessment. *Pharmaceutics* [Internet]. 2022 Jun 16;14(6):1279. Available from: <https://www.mdpi.com/1999-4923/14/6/1279>
 14. Tang Cheng, Kun Meng 2, Xiaoming Chen 2, Hua Yao 2, Junqiong Kong 2, Fusu Li 2, Haiyan Yin 2, Mingji Jin 2, Hao Liang 1 and QY 1. Preparation, Characterization, and In Vivo Evaluation of Amorphous Icaritin Nanoparticles Prepared by a Reactive Precipitation Technique. 2021;3:8–11.
 15. Zheng Y, Zhao C, Chen B, Teng H, Ai C, Chen L. D- α -tocopherol polyethylene glycol 1000 succinate-based microemulsion delivery system: Stability enhancement of physicochemical properties of luteolin. *Food Chemistry* [Internet]. 2023 Nov;426:136587. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0308814623012050>
 16. Das T, Chatterjee N, Chakraborty A, Banerjee A, Haitti SB, Datta S, et al. Fabrication of rice bran oil nanoemulsion and conventional emulsion with Mustard Protein Isolate as a novel excipient: Focus on shelf-life stability, lipid digestibility and cellular bioavailability. *Food Hydrocolloids for Health* [Internet]. 2023 Dec;4:100143. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2667025923000286>
 17. Kumara BN, Shambhu R, Shim Y-B, Nirmal J, Prasad KS. Development of mucoadhesive Timolol loaded chitosan-nanocomposite to treat glaucoma. *International Journal of Biological Macromolecules* [Internet]. 2023 Dec;253:126917. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S014181302303814X>
 18. Wang L, Mao J, Zhou Q, Deng Q, Zheng L, Shi J. A curcumin oral delivery system based on sodium caseinate and carboxymethylpachymaran nanocomposites. *International Journal of Biological Macromolecules* [Internet]. 2023 Dec;253:126698. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S014181302303595X>
 19. ElNashar NT, Breitingner U, Breitingner H-G, Mansour S, Tammam SN. A liposomal platform for the delivery of ion channel proteins for treatment of channelopathies — Application in therapy of cystic fibrosis. *International Journal of Biological Macromolecules* [Internet]. 2023 Dec;253:126652. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0141813023035493>
 20. Fitrya F, Fithri NA, Ahmadi A, Wijaya DP, Pitaloka AD. Formulation and characterization of transfersome gel from *Parkia speciosa* extract using carbopol 940 and polyvinyl alcohol. *Medicinal Plants - International Journal of Phytomedicines and Related Industries* [Internet]. 2022;14(3):499–506. Available from: <http://www.indianjournals.com/ijor.aspx?target=ijor:mpijpri&volume=14&issue=3&article=016>
 21. Lin M, Wu L, Lu Y, Bao X, Zhong H, Dai Q, et al. Membrane fusion reverse micelle platforms as potential oral nanocarriers for efficient internalization of free hydrophilic peptides. *Nano Research* [Internet]. 2023 Jul 14;16(7):9768–80. Available from: <https://link.springer.com/10.1007/s12274-023-5645-7>
 22. El-Say KM, Alamri SH, Alsulimani HH, Alharbi WS, Omar AM, Safo MK, et al. Incorporating valsartan in sesame oil enriched self-nanoemulsifying system-loaded liquisolid tablets to improve its bioavailability. *International Journal of Pharmaceutics* [Internet]. 2023 May;639:122966. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0378517323003861>
 23. Suhery WN, Mudhakir D, Sumirtapura YC, Pamudji JS. Comparative Bioavailability Study of Solid Self-Nanoemulsifying Drug Delivery System of Fenofibric Acid in Healthy Male Subjects. *Medical Principles and Practice* [Internet]. 2022;31(2):142–8. Available from: <https://www.karger.com/Article/FullText/522380>
 24. R. Gardouh A, M. Nasef A, Mostafa Y, Gad S. Impact on HDL and LDL of Hyperlipidemic

- Rat Models: Designed Solid Self-Nanoemulsifying Drug Delivery Systems with Atorvastatin and Ezetimibe combination. Research Journal of Pharmacy and Technology [Internet]. 2022 Jun 28;2459–69. Available from: <https://rjptonline.org/AbstractView.aspx?PID=2022-15-6-15>*
25. Bravo-Alfaro DA, Ochoa-Rodríguez LR, Villaseñor-Ortega F, Luna-Barcenas G, García HS. Self-nanoemulsifying drug delivery system (SNEDDS) improves the oral bioavailability of betulinic acid. *Journal of Molecular Liquids [Internet]. 2022 Oct;364:119946. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0167732222014842>*
 26. Abdullah M, Kanwal T, Shuja AA, Rao K, Rehman K, Kawish M, et al. Synthesis and characterization of cinnamic acid based glyceride and its application for developing self-nanoemulsifying drug delivery system for curcumin oral delivery. *Journal of Molecular Structure [Internet]. 2022 Sep;1263:133131. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0022286022007918>*
 27. Chavda H, Patel J, Chavada G, Dave S, Patel A, Patel C. Self-Nanoemulsifying Powder of Isotretinoin: Preparation and Characterization. *Journal of Powder Technology. 2013;2013:1–9.*
 28. Jain S, Kumar N, Sharma R, Ghadi R, Date T, Bhargavi N, et al. Self-nanoemulsifying formulation for oral delivery of sildenafil: effect on physicochemical attributes and in vivo pharmacokinetics. *Drug Delivery and Translational Research [Internet]. 2023 Mar 12;13(3):839–51. Available from: <https://link.springer.com/10.1007/s13346-022-01247-x>*
 29. Dewantara Putra Igna, Murwanti R, Rohman A, Sulaiman T. S. Optimizing Formulation Of Mini Tablets Floating Ranitidine Hcl Using Fully Pregelatinized Starch (*Manihot Esculenta* Crantz) With Simplex Lattice Design. *International Journal of Applied Pharmaceutics [Internet]. 2019 Apr 11;11(4):32–40. Available from: <https://innovareacademics.in/journals/index.php/ijap/article/view/32657>*
 30. Nipanikar S, Nagore D, Chitlange S. Evaluation of aphrodisiac activity of AHPL/AYCAP/0114 capsule in sexually sluggish male rats. *Pharmacognosy Magazine [Internet]. 2018;14(55):264. Available from: <https://phcog.com/article/view/2018/14/55s/264-s267>*
 31. Sunkara D, Capece M. Influence of Material Properties on the Effectiveness of Glidants Used to Improve the Flowability of Cohesive Pharmaceutical Powders. *AAPS PharmSciTech [Internet]. 2018 May 16;19(4):1920–30. Available from: <http://link.springer.com/10.1208/s12249-018-1006-3>*
 32. Kuruba G, Narayana Reddy KA, Poli S, Ramnarayanan C. Quality by Design Based Development of Self Nano Emulsifying Drug Delivery System of Ritonavir. *Journal of Young Pharmacists. 2020;12(3):215–20.*
 33. Bhagwat DA, Swami PA, Nadaf SJ, Choudhari PB, Kumbar VM, More HN, et al. Capsaicin Loaded Solid SNEDDS for Enhanced Bioavailability and Anticancer Activity: In-Vitro, In-Silico, and In-Vivo Characterization. *Journal of Pharmaceutical Sciences [Internet]. 2021 Jan;110(1):280–91. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0022354920306122>*
 34. Navaneetha K, Rao VVB. Formulation and Evaluation of Solid-Supersaturable-SNEDDS of Ibrutinib. *Indonesian Journal of Applied Pharmaceutics. 2022;14(5).*
 35. Tashish AY, Shahba AAW, Alanazi FK, Kazi M. Adsorbent Precoating by Lyophilization: A Novel Green Solvent Technique to Enhance Cinnarizine Release from Solid Self-Nanoemulsifying Drug Delivery Systems (S-SNEDDS). *Pharmaceutics. 2023;15(1).*
 36. Fisher KJ, Kinsey R, Mohamath R, Phan T, Liang H, Orr MT, et al. Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions. *npj Vaccines. 2023;8(1):1–19.*
 37. Ozturk M, Hakeem KR. *Plant and Human Health, Volume 1 Ethnobotany and Physiology.*

- Switzerland: Speinger International Publishing AG; 2019.
38. Sun X-G, Pang X, Liang H-Z, Zhang J, Wang B, Li Q, et al. New prenylated flavonoid glycosides derived from *Epimedium wushanense* by β -glucosidase hydrolysis and their testosterone production-promoting effects. *Chinese Journal of Natural Medicines* [Internet]. 2022 Sep;20(9):712–20. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1875536422601882>.